Robust forecasting is a crucial tool for pharma and biotech companies. It guides strategies, reduces risk, and fuels innovation. Evaluate Pharma is the go-to source for consensus forecasts for pharma firms, investment banks, and consultancies.
You can access a richer, insight-driven perspective that uniquely connects consensus forecasts with pipelines across indications, therapeutic areas, and mechanisms of action. Equip your teams with the right details at the right time, ensuring alignment with future goals and a strong competitive position.
Commercial teams, including Business Development & Licensing, Corporate Strategy, and Competitive Intelligence use Evaluate Pharma for asset screening, market analysis, and portfolio strategy. Evaluate Pharma reduces the cost, time and risk associated with making strategic decisions.
Evaluate’s transparent aggregation of the latest commercial analysis provides a single source for your strategic advice. Get quick and easy access to global and regional market assessments, trends in therapeutic areas, competitor analysis and commercial due diligence.
Investment banks, private equity and venture capital firms use Evaluate Pharma to support their investment decision-making. Access insight into market sizing, portfolio and company valuations and assess the impact of market events on share price to provide vital context.
Accessing the breadth and depth of quality, validated data you need can be a real challenge. The different data sets required are hard to source, standardize, aggregate and correlate. And even if you can manage all that in-house, an independent perspective will help to eliminate unconscious bias, de-risk asset valuation and support portfolio optimization decisions. Use consensus forecasting to identify market potential, opportunities and risks so you understand the market view on competitors and product portfolios, and can validate the assumptions that inform investment decisions.
Access consensus forecasts for almost 6,000 drugs, enhanced by the most comprehensive coverage of drug sales at an indication level with coverage of 5,000 drugs at a worldwide level and 2,500 drugs at a US-specific level.
Understand drug progression and identify trends with 1.5m+ consensus forecasts of 10,000 products dating back to 2003.
Identify outliers, and potential under- or over-forecasting for an indication over time.
Monitor deals by company, product, therapy area, and more. Access historical deal data, venture financing and IPO information, key patent expiration dates and sales at risk globally.
View a daily and weekly round-up of the stock price winners and losers, and the news impacting share prices and valuations.
Get insight into future critical events related to a product’s life cycle, and development and regulatory timelines.
Get in touch with our team to explore the right solutions for your business.
